Britta Bonn

Dr. Britta Bonn


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
BBBritta Bonn
Britta Bonn
PSPetter Svanberg
Petter Svanberg
AJAnnika Janefeldt
Annika Janefeldt
IHIa Hultman
Ia Hultman
KGKenneth H Grime
Kenneth H Grime
A key requirement in Drug Discovery is to accurately define intrinsic clearance (CLint) values of less than 1 μL/min/106 hepatocytes. This requires assays that allow for longer incubation time as a complement to suspended hepatocytes. This study assessed the effectiveness of plated HepaRG cells, plated primary human hepatocytes (PHH) and the HμREL® human hepatocyte/stromal cell co-culture for determination of low CLint values. The investigation demonstrated that the systems were capable of providing statistically significant CLint estimations down to 0.2 μL/min/106 cells. The HμREL® assay provided a higher level of reproducibility, with repeat significant CLint values being defined in a minimum of triplicate consecutive assays for 6/7 of the low CLint compounds, compared to 4/7 for PHH and 2/7 for HepaRG. The assays were also compared with a suspension assay using drugs with higher CLint values and diverse enzymology. The CLint values from the PHH and HμREL® assays were similar to those defined by a hepatocyte suspension assay, indicating that they can be used inter-changeably alongside a standard assay. Finally, data from these two assays could also predict in vivo hepatic metabolic CLint to within 3-fold for greater than 70% of the compounds tested, with average fold errors (AFE) of 1.6 and 2.3 respectively; whereas the HepaRG data was predictive to within 3-fold for only 50% of compounds (AFE 2.9). In summary all systems have utility for low CLint determination, but the HμREL® co-culture appears slightly superior regarding overall assay performance.

11 October 2010 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
BBBritta Bonn
Britta Bonn
CLCarina Leandersson
Carina Leandersson
FFFabien Fontaine
Fabien Fontaine
IZIsmael Zamora
Ismael Zamora

1 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KRKatarina Rubin
Katarina Rubin
PEPär Ewing
Pär Ewing
EBErica Bäckström
Erica Bäckström
AAAnna Abrahamsson
Anna Abrahamsson
BBBritta Bonn
Britta Bonn
KGKen Grime
Ken Grime
Significant pulmonary metabolism of inhaled drugs could have drug safety implications or influence pharmacological effectiveness. To study this in vitro, lung microsomes or S9 are often employed. Here, we have determined if rat and human lung microsomes are fit for purpose or whether it is better to use specific cells where drug-metabolizing enzymes are concentrated, such as alveolar type II (ATII) cells. Activities for major hepatic and pulmonary human drug-metabolizing enzymes are assessed and the data contextualized towards an in vivo setting using an ex vivo isolated perfused rat lung model. Very low rates of metabolism are observed in incubations with human ATII cells when compared to isolated hepatocytes and fewer of the substrates are found to be metabolized when compared to human lung microsomal incubations. Reactions selective for flavin-containing monooxygenases (FMOs), CYP1B1, CYP2C9, CYP2J2, and CYP3A4 all show significant rates in human lung microsomal incubations, but all activities are higher when rat lung microsomes are used. The work also demonstrates that a lung microsomal intrinsic clearance value towards the lower limit of detection for this parameter (3 µL/min/mg protein) results in a very low level of pulmonary metabolic clearance during the absorption period, for a drug dosed into the lung in vivo.

15 December 2015 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMarie Brännström
Marie Brännström
PNPär Nordell
Pär Nordell
BBBritta Bonn
Britta Bonn
ADAndrew M. Davis
Andrew M. Davis
APAnna-Pia Palmgren
Anna-Pia Palmgren
KGKen Grime
Ken Grime
Clinical studies with montelukast show variability in effect and polymorphic OATP2B1-dependent absorption has previously been implicated as a possible cause. This claim has been challenged with conflicting data and here we used OATP2B1-transfected HEK293 cells to clarify the mechanisms involved. For montelukast, no significant difference in cell uptake between HEK-OATP2B1 and empty vector cell lines was observed at pH 6.5 or pH 7.4, and no concentration-dependent uptake was detected. Montelukast is a carboxylic acid, a relatively potent inhibitor of OATP1B1, OATP1B3, and OATP2B1, and has previously been postulated to be actively transported into human hepatocytes. Using OATP1B1-transfected HEK293 cells and primary human hepatocytes in the presence of OATP inhibitors we demonstrate for the first time that active OATP-dependent transport is unlikely to play a significant role in the human disposition of montelukast.